Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2016

MarketResearchReports.biz has recently announced the addition of a market study “ Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia Pipeline Review, H2 2016, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 46, 42, 65 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 14 and 2 molecules, respectively.Acute Lymphocytic Leukemia.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/873441

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).

– The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. ognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Content

Table of Contents 2

Introduction 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8

Therapeutics Development 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics under Development by Companies 11

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics under Investigation by Universities/Institutes 18

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Products Glance 20

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Products under Development by Companies 23

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Products under Investigation by Universities/Institutes 34

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Companies Involved in Therapeutics Development 36

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics Assessment 126

Drug Profiles 148

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects 642

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products 649

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Product Development Milestones 651

Appendix 659

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 (Contd..1) 32

Number of Products under Development by Companies, H2 2016 (Contd..2) 33

Number of Products under Development by Companies, H2 2016 (Contd..3) 34

Number of Products under Development by Companies, H2 2016 (Contd..4) 35

Number of Products under Development by Companies, H2 2016 (Contd..5) 36

Number of Products under Development by Companies, H2 2016 (Contd..6) 37

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 40

Comparative Analysis by Clinical Stage Development, H2 2016 41

Comparative Analysis by Early Stage Development, H2 2016 42

Products under Development by Companies, H2 2016 43

Products under Development by Companies, H2 2016 (Contd..1) 44

Products under Development by Companies, H2 2016 (Contd..2) 45

Products under Development by Companies, H2 2016 (Contd..3) 46

Products under Development by Companies, H2 2016 (Contd..4) 47

Products under Development by Companies, H2 2016 (Contd..5) 48

Products under Development by Companies, H2 2016 (Contd..6) 49

Products under Development by Companies, H2 2016 (Contd..7) 50

Products under Development by Companies, H2 2016 (Contd..8) 51

Products under Development by Companies, H2 2016 (Contd..9) 52

Products under Development by Companies, H2 2016 (Contd..10) 53

Products under Investigation by Universities/Institutes, H2 2016 54

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 55

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by 4SC AG, H2 2016 56

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 57

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at http://www.marketresearchreports.biz/pressreleases

Contact

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net